

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		20-4518P U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/JP98/02781	June 23, 1998	June 25, 1997
TITLE OF INVENTION A STABLE OINTMENT CONTAINING ASPIRIN		
APPLICANT(S) FOR DO/EO/US MIZOBUCHI, Noriko; HASEGAWA, Yuichi; KAWADA, Mitsuhiro; HISAIUCHI, Shin-ichi		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p>		
<p>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(3)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(2)).</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p>		
<p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
<p>Items 11. to 16. below concern document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information: 1) PCT/ISA/210 International Search Report</p>		

17. The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):**Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. **\$970.00**International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$930.00**International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. **\$760.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$670.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **\$96.00****ENTER APPROPRIATE BASIC FEE AMOUNT =**Surcharge of **\$130.00** for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS NUMBER FILED NUMBER EXTRA RATE

Total Claims 3 - 20 = 0 X \$18.00 \$ 0.00

Independent Claims 2 - 3 = 0 X \$78.00 \$ 0.00

MULTIPLE DEPENDENT CLAIM(S) (if applicable) NO + \$260.00 \$ 0.00

TOTAL OF ABOVE CALCULATIONS = \$ 1,060.00Reduction of $\frac{1}{2}$ for filing by small entity, if applicable. Verified Small Entity statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).**SUBTOTAL =** \$ 1,060.00Processing fee of **\$130.00** for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).**TOTAL NATIONAL FEE =** \$ 1,060.00Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +**TOTAL FEES ENCLOSED =** \$ 1,060.00Amount to be:
refunded

\$

charged

\$

a. A check in the amount of **\$ 1,060.00** to cover the above fees is enclosed.b. Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2448.**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

Send all correspondence to:

Birch, Stewart, Kolasch & Birch, LLP
P.O. Box 747
Falls Church, VA 22040-0747
(703)205-8000

 SIGNATURE
Faraci, C. JOSEPH
 NAME
32,350
REGISTRATION NUMBER

/am February 24, 1999

09/242700
410 Rec'd PCT/PTO 24 FEB 1999

20-4518P

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT: Noriko MIZOBUCHI et al.

INT'L. APPLN. NO.: PCT/JP98/02781

SERIAL NO.: NEW

GROUP:

FILED: February 24, 1999

EXAMINER:

FOR: A STABLE OINTMENT CONTAINING ASPIRIN

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
and Trademarks
BOX PATENT APPLICATION
Washington, D.C. 20231

February 24, 1999

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION:

Before line 1, insert --This application is the national phase under 35 U.S.C. §371 of prior PCT International Application No. PCT/JP98/02781 which has an International filing date of June 23, 1998 which designated the United States of America.--

REMARKS


The specification has been amended to provide a cross-reference to the previously filed International Application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By



C. JOSEPH FARACI
Reg. No. 32,350
P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

DESCRIPTION

A stable ointment containing Aspirin

5 Technical Field

The present invention relates to a stable ointment containing Aspirin (acetyl salicylic acid).

More specifically, the present invention relates to a substantially anhydrous ointment containing Aspirin characterized in using hydrocarbon gel and/or vaseline (petrolatum) as a base, which can preserve Aspirin stably for a long term.

Background Art

15 Aspirin has been used as an anti-inflammatory antipyretic analgesics from of old. It is in general orally administered in form of tablets, granules and so on.

However, due to the intestinal injury by Aspirin, its external application has been recently studied and it has 20 been done to try to make it percutaneously absorb. The results are reported in Japanese Patent Pub. No. 3-72426 in form of ointments for treatment of neuralgia, in Japanese Patent Pub. No. 6-72879 in form of patches containing Aspirin, in Japanese Patent Pub. No. 6-183980 as a 25 stabilizing method of Aspirin in patches containing it.

Further, patches containing Aspirin are disclosed in Japanese Patent Pub. No. 8-113531. Techniques such as improvement of transdermal absorption of Aspirin and stabilization of it in plasters are mainly disclosed in 5 these publications. However, any technique to maintain Aspirin stably in ointments for a long term is not disclosed.

The literatures which describe methods for 10 stabilization of Aspirin in preparations except for external preparations, are Japanese Patent Pub. No. 56-32425, Japanese Patent Pub. No. 62-89619, Japanese Patent Pub. No. 4-346930 and so on.

Because Aspirin is readily hydrolyzed even in the 15 presence of small amount of water and furthermore, by depending on a kind of additives the hydrolysis is accelerated, in these literatures in order to avoid to contact with the additive, it is disclosed to use the protective layer consisting of sucrose, or to use binders in which water was excluded as much as possible degree and 20 to add a hydrogenated oil as a lubricant. However, it is hardly possible to apply such techniques to ointments.

As such, in external preparations of Aspirin, the technique to secure the stability of Aspirin in preparing ointments has not been shown.

25 Disclosure Of Invention

The present invention was made in considering of the above problems and the object of the present invention is to provide ointments containing Aspirin which are superior in stability and can be stored for a long term.

5 That is, by preparing substantially water free-ointments prepared by adding Aspirin to a base comprising hydrocarbon gel and/or vaseline (petrolatum) it was found to solve the above problems and thus the present invention was completed.

10 Hydrocarbon gel and vaseline in the present invention are used in substantially anhydrous state. Vaseline is one ordinary used as a base for preparation of ointments, such as yellow vaseline, white vaseline and their mixture.

15 The amount of Aspirin in an ointment of the present invention is 0.001 to 30% by weight, preferably 0.01 to 20% by weight, more preferably 0.05 to 15% by weight. In case of more than 30% by weight of Aspirin, it is impossible to maintain the property of ointments and in addition the protection effect by the base decreases to cause hydrolysis 20 of Aspirin. On the other hand, in case of less than 0.001% by weight of Aspirin it is hardly to exhibit the pharmacological activities of Aspirin. Either case is not preferable.

25 The ointments of the present invention containing Aspirin are prepared by the same method as ordinal

PENTECO LTD.

ointments. That is, after melting a base by warming, thereto fine powders of Aspirin are added under stirring and mixed to prepare ointments.

5 In case of preparation of these ointments, to add water in order to dissolve Aspirin and the like is not preferable and should be avoided.

Furthermore, it is not preferable to add any additive which destroys stability of Aspirin, such as an organic acid, an alcohol, a polyhydric alcohol, a surfactant, etc.

10

Best Mode for Carrying Out the Invention

The present invention is shown in more detail by the following examples. But the present invention is not limited by the examples.

15

Example 1

According to the following ingredients, white vaseline was put in a vacuum emulsifier (T.K.ROBO MIXER prepared by Tokusyukika Kogyo) to be melted under heating at 55 °C. Thereto Aspirin was added and the mixture was stirred under vacuum at 2,000rpm for 15 minutes. Then the mixture was cooled to 25 °C to give ointments containing Aspirin.

25

<u>Ingredients</u>	<u>Contents</u>
Aspirin	0.5g
White vaseline	99.5g

5 Example 2

According to the following ingredients, yellow vaseline and Aspirin were put in a grinder and the mixture was stirred at 100rpm to give ointments containing Aspirin.

10	<u>Ingredients</u>	<u>Contents</u>
Aspirin	8.0g	
Yellow vaseline	92.0g	

Example 3

15 According to the following ingredients, hydrocarbon gel and Aspirin were put in a grinder and the mixture was stirred at 80rpm to give ointments containing Aspirin.

20	<u>Ingredients</u>	<u>Contents</u>
Aspirin	5.0g	
Hydrocarbon gel	99.5g	
(Japanese Pharmaceutical Excipients)		

Example 4

25 According to the following ingredients, hydrocarbon

gel and Aspirin were put in a planetary mixer and the mixture was stirred under vacuum at 130rpm for 20 minutes to give ointments containing Aspirin.

5	<u>Ingredients</u>	<u>Contents</u>
	Aspirin	25.0g
	Hydrocarbon gel	75.0g
(Japanese Pharmaceutical Excipients)		

10 Example 5

According to the following ingredients and the method described in Example 4, there were obtained ointments containing Aspirin.

15	<u>Ingredients</u>	<u>Contents</u>
	Aspirin	0.5g
	Hydrocarbon gel	99.5g
(Japanese Pharmaceutical Excipients)		

20 Example 6

According to the following ingredients and the method described in Example 4, there were obtained ointments containing Aspirin.

	<u>Ingredients</u>	<u>Contents</u>
	Aspirin	1.0g
	Hydrocarbon gel	79.0g
	(Japanese Pharmaceutical Excipients)	
5	White vaseline	20.0g

Comparative Example 1

According to the following ingredients, polyacrylic acid was added to propylene glycol and the mixture was melted by warming on a water bath and stirred. Then, Aspirin was dissolved in the mixture and thereto triethanolamine was added. The mixture was stirred to give gelation ointments.

	<u>Ingredients</u>	<u>Contents</u>
15	Aspirin	0.5g
	Polyacrylic acid	0.5g
	Propylene glycol	45.0g
	Triethanolamine	0.67g
20	Purified water	residual
	Total	100.0g

Comparative Example 2

According to the following ingredients, carboxymethyl cellulose sodium was dispersed in ethanol. The mixture was

added to a mixture of glycerin and propylene glycol under stirring. Then, Aspirin was dispersed and dissolved in the mixture. Thereto purified water was added and the mixture was stirred thoroughly to give gelation ointments.

5

	<u>Ingredients</u>	<u>Contents</u>
	Aspirin	0.5g
	Carboxymethyl cellulose sodium	6.0g
	Ethanol	8.0g
10	Glycerin	20.0g
	Propylene glycol	20.0g
	Purified water	residual
	Total	100.0g

15 Comparative Example 3

According to the following ingredients, hydrophilic ointments described in the Pharmacopeia of Japan XIII was prepared and thereto Aspirin was mixed to prepare a ointment.

20

Ingredient of hydrophilic ointment

	White vaseline	25.0g
	Stearyl alcohol	20.0g
	Propylene glycol	12.0g
25	Polyoxyethylene hydrogenated castor oil	4.0g

Glycerol monostearate	1.0g
p-Hydroxybenzoic acid methyl ester	0.1g
p-Hydroxybenzoic acid propyl ester	0.1g
Purified water	residual
5	Total 100.0g

Ingredients of ointment containing Aspirin

Aspirin	0.5g
Hydrophilic ointment	99.5g

10

Experiment 1

Ointments of the present invention prepared by Examples 1 and 5, and ointments prepared by Comparative Examples 1 to 4 were tested on stability in strage at 75% RH at 40°C, and at 50°C. Test samples were stored under each condition for one or two months, and after sampling, contents of Aspirin remaining in each sample were measured and the remaining percentage per initial contents was calculated and shown in Table 1.

15

Experiment 2

Ointments of the present invention prepared by examples 1 to 5 and ointments prepared by Comparative Example 1 were measured on the water contents in them by 25 Karl-Fischer moisture content meter and the results were

shown in Table 2.

Table 1. Test result on the stability of ointments containing Aspirin

5

	75%RH at 40°C				at 50°C			
	Initial	remain (%)			Initial	remain (%)		
		1	2	10.5		1	2	10.5
Example 1	100	100.6	1002.4	96.9	100	96.0	97.8	91.7
Example 5	100	101.2	1002.4	96.4	100	100.0	99.4	93.2
Comp. Ex.1	1001	15.4	1.2	0	100	0.8		0
Comp. Ex.2	100	13.8	1.4	0	100	0	0	
Comp. Ex.3	100	20.7	0.4	0	100	0	0	

Table 2. The result of measurement of water content in ointments containing Aspirin

	Ex.1	Ex.2	Ex.3	Ex.4	Ex.5	Com.Ex.1	Com.Ex.2	Com.Ex.3
water contents (%)	0.0190	0.0261	0.0098	0.0127	0.0066	55.2438	45.2190	38.0261

10

Industrial Applicability

The ointments of the present invention containing Aspirin can be stored stably Aspirin for a long term in form of the substantially anhydrous ointment containing hydrocarbon gel

15

and/or vaseline as a base.

CLAIMS

1. A substantially anhydrous ointment containing Aspirin which is characterized in using hydrocarbon gel and/or 5 vaseline as a base.

2. A stable ointment containing Aspirin and a base consisting of at least one compound selected from hydrocarbon gel and vaseline.

3. The ointment of claim 2 wherein the content of Aspirin 10 0.001 to 30% weight per total amount.

C O N T I N U E D

ABSTRACT

A substantially anhydrous stable ointment containing Aspirin which is characterized in using gelation hydrocarbon and/or vaseline as a base. The ointment is superior in stability and can be stored for a long term.

the first time in the history of the world, the *whole* of the human race, in all its parts, has been brought together in a single, common, and universal language.

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Terrell C. Birch (Reg. No. 19,382)
 Joseph A. Kolasch (Reg. No. 22,468)
 Bernard L. Sweeney (Reg. No. 24,449)
 Charles Gorenstein (Reg. No. 29,271)
 Leonard R. Svensson (Reg. No. 30,320)
 Andrew D. Meikle (Reg. No. 32,868)
 Joe McKinney Muncy (Reg. No. 32,934)
 C. Joseph Faraci (Reg. No. 32,350)

Raymond C. Stewart (Reg. No. 21,066)
 James M. Slattery (Reg. No. 28,380)
 Michael K. Mutter (Reg. No. 29,680)
 Gerald M. Murphy, Jr. (Reg. No. 28,977)
 Terry L. Clark (Reg. No. 32,644)
 Marc S. Weiner (Reg. No. 32,181)
 Andrew F. Reish (Reg. No. 33,449)
 Donald J. Daley (Reg. No. 34,313)

Send Correspondence to:

BIRCH, STEWART, KOLASCH & BIRCH, LLP

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:
 YOU MUST
 COMPLETE THE
 FOLLOWING:



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or Sole Inventor:
 Notiiko MIZOBUCHI
 Residence (City, State & Country):
 Kochi-shi, Kochi-ken, Japan
 POST OFFICE ADDRESS (Complete Street Address including City, State & Country):
 Raionzuhiru-Kochi 1212, 10-45, Hijima-cho 2-chome, Kochi-shi, Kochi-ken, Japan
 Full Name of Second Inventor, if any:
 Yuichi HASEGAWA
 Residence (City, State & Country):
 Kakogawa-shi, Hyogo-ken, Japan
 POST OFFICE ADDRESS (Complete Street Address including City, State & Country):
 24-1, Hirano, Kakogawa-cho, Kakogawa-shi, Hyogo-ken, Japan
 Full Name of Third Inventor, if any:
 Mitsuhiko KAWADA
 Residence (City, State & Country):
 Ohkawa-gun, Kagawa-ken, Japan
 POST OFFICE ADDRESS (Complete Street Address including City, State & Country):
 313-22, Machida, Ochi-cho, Ohkawa-gun, Kagawa-ken, Japan
 Full Name of Fourth Inventor, if any:
 Shin-ichi HISAIKI
 Residence (City, State & Country):
 Kita-gun, Kagawa-ken, Japan
 POST OFFICE ADDRESS (Complete Street Address including City, State & Country):
 2050-20, Hikami, Miki-cho, Kita-gun, Kagawa-ken, Japan
 Full Name of Fifth Inventor, if any:
 see above

see above

see above

see above

see above

GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Notiiko	MIZOBUCHI	Notiiko Mizobuchi	03/18/1999
Residence (City, State & Country): Kochi-shi, Kochi-ken, Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country): Raionzuhiru-Kochi 1212, 10-45, Hijima-cho 2-chome, Kochi-shi, Kochi-ken, Japan			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Yuichi	HASEGAWA	Yuichi Hasegawa	03/18/1999
Residence (City, State & Country): Kakogawa-shi, Hyogo-ken, Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country): 24-1, Hirano, Kakogawa-cho, Kakogawa-shi, Hyogo-ken, Japan			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Mitsuhiko	KAWADA	Mitsuhiko Kawada	03/18/1999
Residence (City, State & Country): Ohkawa-gun, Kagawa-ken, Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country): 313-22, Machida, Ochi-cho, Ohkawa-gun, Kagawa-ken, Japan			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Shin-ichi	HISAIKI	Shin-ichi Hisaiki	03/18/1999
Residence (City, State & Country): Kita-gun, Kagawa-ken, Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country): 2050-20, Hikami, Miki-cho, Kita-gun, Kagawa-ken, Japan			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country):		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country):			

* DATE OF SIGNATURE